首页 | 本学科首页   官方微博 | 高级检索  
     


The prevalence and clinical significance of 18F–2‐fluoro‐2‐deoxy‐D‐glucose (FDG) uptake in the thyroid gland on PET or PET‐CT in patients with lymphoma
Authors:Michael Lin  Christine Wong  Peter Lin  Ivan Ho Shon  Ramesh Cuganesan  Seu Som
Affiliation:1. Liverpool Hospital, University of New South Wales, Liverpool, New South Wales 2170, Australia;2. Department of Nuclear Medicine and PET, Liverpool Hospital, Liverpool, New South Wales 2170, Australia;3. Department of Diagnostic Radiology, Liverpool Hospital, Liverpool, New South Wales 2170, Australia
Abstract:F18–2‐fluoro‐2‐deoxy‐D‐glucose (FDG) positron emission tomography (PET) has become a well established tool in staging and assessing therapy response in lymphoma. Incidental thyroid uptake on PET is not uncommon and can pose a diagnostic and management challenge. We retrospectively evaluate the prevalence and clinical significance of incidental FDG uptake in the thyroid gland in patients with lymphoma. 1868 lymphoma patients underwent PET and PET‐CT between August 2002 and August 2008. 52 patients (2.8%) demonstrated FDG thyroid uptake (M = 17, F = 35; mean age 63 yr). Thyroid uptake was determined as focal or diffuse, maximum standardized uptake values (SUVmax) recorded as well as SUV max ratio compared to background mediastinum activity (SUVR). Corresponding CT findings on PET‐CT were evaluated independently. Results were correlated with clinical, histopathological and imaging follow‐up. 30 (1.6%) patients had focal thyroid uptake. 16 (53%) had histological confirmation either by surgery (n = 7) or FNA under USS (n = 9). The final diagnosis was benign in 12/30 patients and malignant in 9/30. The malignancy risk for focal thyroid uptake was 30%. Five patients had intercurrent thyroid cancer (four papillary, one microinvasive follicular) and four had lymphomatous involvement. There was no significant difference between the mean sizes of benign (23.7 mm, range 12–34) and malignant nodules (23.6 mm, range 8–48). The mean SUVmax of malignant and benign nodules was 4.4 (range 1.8–10.1) and 3.2 (range 1.8–6.9) respectively with no statistically significant difference. 22 (1.2%) patients had diffuse FDG uptake in thyroid and benign aetiology was found in all with adequate follow‐up (15/22). Focal FDG thyroid uptake on PET or PET‐CT in lymphoma patients warrants further investigations. The malignancy risk is 30% either due to intercurrent thyroid cancer or lymphomatous involvement. SUVmax, SUVR and CT attenuation characteristics are not helpful in distinguishing between benign and malignant aetiologies. Diffuse thyroid uptake has a benign aetiology. Copyright © 2010 John Wiley & Sons, Ltd.
Keywords:FDG  PET  PET‐CT  positron emission tomography  thyroid  lymphoma  NHL
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号